Abstract
This cross-sectional study was conducted to examine whether the obstructive sleep apnea syndrome (OSAS) is associated with elevation of the pulse wave velocity (PWV) and increase in the plasma levels of C-reactive protein (CRP), both of which are known markers of cardiovascular risk, and also to determine if the concurrent presence of the metabolic syndrome might exacerbate this elevation in the levels of these cardiovascular risk markers in subjects with OSAS. With these objectives, the PWV and serum CRP were measured in 184 subjects attending a sleep clinic. It was found that the PWV and CRP were higher in the subjects with OSAS (n=94) than in those without OSAS (n=90). Furthermore, among the subjects with OSAS, the PWV and CRP were higher in those with the concurrent presence of the metabolic syndrome (n= 41; PWV=1,562±19 cm/s; CRP=1.8±0.2 mg/l) than in those without metabolic syndrome (n=53; PWV=1,432±21 cm/s; CRP=1.2±0.1 mg/l) (p<0.05). A general linear model analysis demonstrated that OSAS and metabolic syndrome were independently associated with elevated PWV and increase of the plasma levels of CRP. OSAS appears to be associated with increased cardiovascular risk, as reflected by both elevated PWV and increase of the plasma CRP. The concurrent presence of metabolic syndrome may exacerbate this increase in cardiovascular risk in subjects with OSAS. Therefore, the concurrent presence of metabolic syndrome may constitute an additive cardiovascular risk factor in subjects with OSAS.
Similar content being viewed by others
Article PDF
References
Mooe T, Franklin KA, Holmstrom K, Rabben T, Wiklund U : Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med 2001; 164: 1910–1913.
Milleron O, Pilliere R, Foucher A, et al: Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur Heart J 2004; 25: 728–734.
Shepertycky MR, Al-Barrak M, Kryger MH : Mobidity and mortality in obstructive sleep apnea syndrome 1: effect of treatment on cardiovascular morbidity. Sleep Biol Rhythms 2003; 1: 15–28.
Budhiraja R, Sharief I, Quan SF : Sleep disordered breathing and hypertension. J Clin Sleep Med 2005; 1: 401–404.
Lakka HM, Laaksonen DE, Lakka TA, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.
Malik S, Wong ND, Franklin SS, et al: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 101: 1239–1244.
Takeuchi H, Saitoh S, Takagi S, et al: Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program–Adult Treatment Panel III to Japanese men—the Tanno and Sobetsu Study. Hypertens Res 2005; 28: 203–208.
Wolk R, Shamsuzzaman AS, Somers VK : Obesity, sleep apnea, and hypertension. Hypertension 2003; 42: 1067–1074.
Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP : Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735–741.
Laurent S, Boutouyrie P, Asmar R, et al: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236–1241.
Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG : Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106: 2085–2090.
Glass CK, Witztum JL : Atherosclerosis. The road ahead. Cell 2001; 104: 503–516.
Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL : Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109 ( Suppl 1): IV6–IV19.
Danesh J, Wheeler JG, Hirschfield GM, et al: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387–1397.
Nagahama H, Soejima M, Uenomachi H, et al: Pulse wave velocity as an indicator of atherosclerosis in obstructive sleep apnea syndrome patients. Intern Med 2004; 43: 184–188.
Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al: Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462–2464.
Choi KM, Lee KW, Seo JA, et al: Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome. Diabetes Res Clin Pract 2004; 66: 57–61.
Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM : Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42–47.
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C : American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–438.
WHO Expert Consultation : Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157–163.
Rechtshaffen A, Kales A ( eds): A Manual of Standardized Terminology: Techniques and Scoring System for Sleep Stages of Human Subjects. Los Angeles, UCLA Brain Information Service/Brain Research Institute, 1968.
American Academy of Sleep Medicine Task Force : Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22: 667–689.
Johns MW : A new methods for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540–545.
Tomiyama H, Yamashina A, Arai T, et al: Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—a survey of 12517 subjects. Atherosclerosis 2003; 166: 303–309.
Yamashina A, Tomiyama H, Takeda K, et al: Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359–364.
van Popele NM, Grobbee DE, Bots ML, et al: Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 2001; 32: 454–460.
Oliver JJ, Webb DJ : Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 2003; 23: 554–566.
London GM, Cohn JN : Prognostic application of arterial stiffness: task forces. Am J Hypertens 2002; 15: 754–758.
Doelle GC : The clinical picture of metabolic syndrome. An update on this complex of conditions and risk factors. Postgrad Med 2004; 116: 30–38.
Jialal I, Devaraj S, Venugopal SK : C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6–11.
Calabro P, Willerson JT, Yeh ET : Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108: 1930–1932.
Ridker PM, Buring JE, Cook NR, Rifai N : C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391–397.
Sattar N, Gaw A, Scherbakova O, et al: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–419.
Tomiyama H, Koji Y, Yambe M, et al: Elevated C-reactive protein augments increased arterial stiffness in subjects with the metabolic syndrome. Hypertension 2005; 45: 997–1003.
Lee WY, Park JS, Noh SY, Rhee EJ, Kim SW, Zimmet PZ : Prevalence of the metabolic syndrome among 40,698 Korean metropolitan subjects. Diabetes Res Clin Pract 2004; 65: 143–149.
Sutton-Tyrrell K, Newman A, Simonsick EM, et al: Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension 2001; 38: 429–433.
Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G : C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord 2001; 25: 1416–1420.
Narkiewicz K, Somers VK : Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol Scand 2003; 177: 385–390.
Huggett RJ, Burns J, Mackintosh AF, Mary DA : Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 2004; 44: 847–852.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shiina, K., Tomiyama, H., Takata, Y. et al. Concurrent Presence of Metabolic Syndrome in Obstructive Sleep Apnea Syndrome Exacerbates the Cardiovascular Risk: A Sleep Clinic Cohort Study. Hypertens Res 29, 433–441 (2006). https://doi.org/10.1291/hypres.29.433
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.29.433
Keywords
This article is cited by
-
Associations between cardiometabolic phenotypes and levels of TNF-α, CRP, and interleukins in obstructive sleep apnea
Sleep and Breathing (2023)
-
Impact of CPAP on arterial stiffness in patients with obstructive sleep apnea: a meta-analysis of randomized trials
Sleep and Breathing (2021)
-
Improving obesity and blood pressure
Hypertension Research (2020)
-
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Hypertension Research (2019)
-
Sleepiness, inflammation and oxidative stress markers in middle-aged males with obstructive sleep apnea without metabolic syndrome: a cross-sectional study
Respiratory Research (2015)